WRONG, the FDA does go against their advisory boards on occasion. Like recently when the FDA approved Pharmacia Upjohn's AIDS drug Rescriptor, despite conflicting evidence of efficacy and a deadlock vote by the advisory panel, where the panel did not recommend the FDA to approve it for marketing primarily because it didn't show efficacy in one of two clinical trials. Yet the FDA approved it last month. They are much more likely to go against the panels and approve, when it involves nasty terminal diseases, than when it is for a cosmetic usage like most dermatological drugs for zits for example.
Also, your last line:
<<<<<<<<
The FDA didn't mind the mortalities in the myotorphin trial becuase they were Europeans, if americans died, they would have been pissed.
>>>>>>
is really callous!!! They were able to adequately explain these deaths and it was not questioned during by the panels.
Rman
PS: I've never owned CEPH and haven't lost money on biotechs, but have made hundreds of thousands on them. Also, if that is what you call a sense of humor, I feel sorry for your family. |
